NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock.

2024年1月24日，纽约（环球通讯社）--Tourmaline Bio，Inc.（“Tourmaline”）（纳斯达克：TRML），一家开发转化药物以显着改善改变生命的免疫和炎症性疾病患者生活的晚期临床生物技术公司，今天宣布启动其普通股的拟议承销公开发行。

All shares of common stock to be sold in the proposed offering will be sold by Tourmaline. In addition, Tourmaline expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the number of shares of common stock sold in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

拟发售的所有普通股将由电气石出售。此外，托玛琳预计将授予承销商30天的期权，以购买不超过发行中出售的普通股数量15%的额外股份。本次发行受市场和其他条件的制约，无法保证是否或何时完成本次发行，也无法保证本次发行的实际规模或条款。

Jefferies, Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. The proposed offering will be made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (“SEC”) on August 15, 2022 and declared effective on August 25, 2022.

Jefferies、Piper Sandler、Guggenheim Securities和Truist Securities担任此次发行的联合账簿管理人。拟议的发售将根据S-3表格上的货架登记声明进行，该声明于2022年8月15日提交给证券交易委员会（“SEC”），并于2022年8月25日宣布生效。

The offering will be made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

本次发售将仅通过补充招股说明书和随附招股说明书的方式进行，补充招股说明书和随附招股说明书构成有效货架登记声明的一部分。与本次发行相关的初步补充招股说明书和随附招股说明书将提交给SEC，并可在SEC网站www.SEC.gov上查阅。

Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, t.

初步补充招股说明书和与本次发行相关的随附招股说明书的副本也可以从以下地址获得：Jefferies LLC，收件人：Equity Syndicate招股说明书Department，520 Madison Avenue，2nd Floor，New York，NY 10022，t。